Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2025 02:30 ET | Source: INVENTIVA

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025

Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le...
November 28, 2025 02:30 ET | Source: INVENTIVA

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
November 25, 2025 15:31 ET | Source: Robbins LLP

MLTX Class Action Reminder – Robbins LLP Reminds MoonLake Immunotherapeutics Stockholders of the Opportunity to Lead the Class Action Lawsuit

Robbins LLP alerts investors to a class action involving MoonLake, alleging misleading statements on a drug candidate’s efficacy.
November 12, 2025 16:47 ET | Source: Robbins LLP

ATYR Investors: Securities Law Firm Robbins LLP Reminds Investors of the Pending Lead Plaintiff Deadline in the Class Action Against aTyr Pharma, Inc.

ATyr Pharma, Inc. is being sued because the Company allegedly mislead investors regarding the efficacy of its drug candidate.
October 27, 2025 17:24 ET | Source: Robbins LLP

MoonLake Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MLTX

A class action alleges MoonLake misled investors about SLK’s Nanobody advantages over BIMZELX. Phase 3 results showed no superiority, sending shares down 8
October 22, 2025 20:40 ET | Source: Robbins LLP

JSPR Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Jasper Therapeutics, Inc. Class Action

Jasper’s stock fell 55% after disclosures that it lacked adequate controls over third-party manufacturers, misstating its compliance and operations.
October 17, 2025 16:52 ET | Source: Robbins LLP

SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action Lawsuit

Savara stock declined 31.7% after the FDA declined to file its MOLBREEVI application, citing incomplete chemistry, manufacturing, and controls information.
October 17, 2025 16:43 ET | Source: Robbins LLP

MLTX Investor Notice: Robbins LLP Reminds Stockholders of the Securities Fraud Class Action Against MoonLake Immunotherapeutics

Robbins LLP is Investigating Allegations that MoonLake Immunotherapeutics (MLTX) Mislead Investors Regarding the Efficacy of its Drug Candidate
October 10, 2025 19:24 ET | Source: Robbins LLP

ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.

Robbins LLP is Investigating Allegations that aTyr Pharma, Inc. (ATYR) Mislead Investors Regarding the Efficacy of its Drug Candidate
September 22, 2025 15:41 ET | Source: Robbins LLP

JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.

Robbins LLP is Investigating Allegations that Jasper Therapeutics, Inc. (JSPR) Misled Investors Regarding the Commercial Prospects of its Lead Product